Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 637 participants.
Also called NCT03299244
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 637 participants
- Sponsor
- Registry
-
NCT03299244
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Hong Kong SAR China, India, Malaysia, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03299244. Randomized; quadruple masking; primary purpose treatment. Start 2018-05-15 (actual); primary completion 2020-04-08 (actual). Results posted on 2021-04-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
- Condition
- Secondary Hyperparathyroidism
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Etelcalcetide
- Intervention (Drug)
- Cinacalcet
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct03299244- Content hash
9c7c3993d35d2fdf8dca5e82cc2142f740ee5b0aca9da7612197124da860b0fd